Literature DB >> 11782542

Structured intermittent treatment for HIV disease: Necessary concession or premature compromise?

Diane V Havlir1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11782542      PMCID： PMC117502          DOI： 10.1073/pnas.022629399

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  29 in total

1.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

2.  Immune control of HIV-1 after early treatment of acute infection.

Authors:  E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

3.  Control of SIV rebound through structured treatment interruptions during early infection.

Authors:  F Lori; M G Lewis; J Xu; G Varga; D E Zinn; C Crabbs; W Wagner; J Greenhouse; P Silvera; J Yalley-Ogunro; C Tinelli; J Lisziewicz
Journal:  Science       Date:  2000-11-24       Impact factor: 47.728

4.  Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.

Authors:  H Hatano; K D Miller; C P Yoder; J A Yanovski; N G Sebring; E C Jones; R T Davey
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

5.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

6.  The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.

Authors:  F García; M Plana; G M Ortiz; S Bonhoeffer; A Soriano; C Vidal; A Cruceta; M Arnedo; C Gil; G Pantaleo; T Pumarola; T Gallart; D F Nixon; J M Miró; J M Gatell
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

7.  HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.

Authors:  L Ruiz; G Carcelain; J Martínez-Picado; S Frost; S Marfil; R Paredes; J Romeu; E Ferrer; K Morales-Lopetegi; B Autran; B Clotet
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

8.  Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Authors:  L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

Review 9.  Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.

Authors:  J M Kilby; P A Goepfert; A P Miller; J W Gnann; M Sillers; M S Saag; R P Bucy
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

10.  Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.

Authors:  K V Heath; R S Hogg; K J Chan; M Harris; V Montessori; M V O'Shaughnessy; J S Montanera
Journal:  AIDS       Date:  2001-01-26       Impact factor: 4.177
View more
  9 in total

Review 1.  Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward.

Authors:  Ume L Abbas; John W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

2.  Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.

Authors:  Galina N Nikolenko; Sarah Palmer; Frank Maldarelli; John W Mellors; John M Coffin; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

3.  Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Sarah Palmer; Frank Maldarelli; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-19       Impact factor: 11.205

4.  Structured Treatment Interruption: Approaches and Risks.

Authors:  Mark Dybul
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.725

5.  Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection.

Authors:  Leor S Weinberger; David V Schaffer; Adam P Arkin
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.

Authors:  Evguenia S Svarovskaia; Rebekah Barr; Xuechun Zhang; Godwin C G Pais; Christophe Marchand; Yves Pommier; Terrence R Burke; Vinay K Pathak
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 7.  Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system.

Authors:  Richard W Price; Steven G Deeks
Journal:  J Neurovirol       Date:  2004       Impact factor: 2.643

8.  Nonlinear observer output-feedback MPC treatment scheduling for HIV.

Authors:  Ryan Zurakowski
Journal:  Biomed Eng Online       Date:  2011-05-27       Impact factor: 2.819

9.  Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.

Authors:  Pablo Tebas; William Keith Henry; Roy Matining; Deborah Weng-Cherng; John Schmitz; Hernan Valdez; Nasreen Jahed; Laurie Myers; William G Powderly; David Katzenstein
Journal:  PLoS One       Date:  2008-04-23       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.